logo

For the Inventor, By the Inventor

Newark, CA, United States of America

Cellerant Therapeutics, Inc.

Calculating rank
USPTO Granted Patents = 17

% Expired Patents = 41.2



Forward Citations = 118

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal Holger Karsunky (10 out of 11 patents)

silverMedal Jagath Reddy Junutula (5 out of 38 patents)

bronzeMedal Ying-Ping Jiang (4 out of 9 patents)

4.  Vasu Jammalamadaka (3 out of 19 patents)

5.  Ping Jiang (3 out of 3 patents)

6.  Rob Tressler (3 out of 3 patents)

7.  Julie Lynne Christensen (3 out of 5 patents)

8.  Timothy C Fong (2 out of 6 patents)

9.  Adrianus Geertrudis Wilhelmus Domen (2 out of 4 patents)

10.  Naoya Tsurushita (1 out of 51 patents)

11.  Sanjeevani Ghone (1 out of 4 patents)

12.  Dmitry Borkin (1 out of 16 patents)

13.  Sean W Smith (1 out of 1 patent)

14.  Sylvia Degrado (1 out of 1 patent)

15.  Leonard G Presta (1 out of 215 patents)


17 patents:

1. 11072662 - Humanized anti-CLL-1 antibodies (2021-07-27),
2. 10898580 - Isoquinolidinobenzodiazepines (2021-01-26),
3. 10723805 - Antibodies specific for CLL-1 (2020-07-28),
4. 10350218 - Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers (2019-07-16),
5. 10301394 - Antibodies that specifically bind to TIM3 (2019-05-28),
6. 9974864 - Isoquinolidinobenzodiazepines (2018-05-22),
7. 9850314 - Antibodies specific for CLL-1 (2017-12-26),
8. 9631026 - Antibodies that specifically bind to TIM3 (2017-04-25),
9. 9504694 - Isoquinolidinobenzodiazepines (2016-11-29),
10. 9371390 - Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof (2016-06-21),
11. 9163090 - Antibodies specific for CLL-1 (2015-10-20),
12. 8877495 - Methods of expanding myeloid cell populations and uses thereof (2014-11-04),
13. 8841418 - Antibodies that specifically bind to TIM3 (2014-09-23),
14. 8715619 - Compositions and methods for treating haematological proliferative disorders of myeloid origin (2014-05-06),
15. 8709715 - Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof (2014-04-29),
Company Overview
Cellerant Therapeutics, Inc. is a biotechnology company based in Newark, California, focused on developing innovative cell therapies for the treatment of various hematologic malignancies and other serious diseases. The company specializes in the research and manufacture of cellular therapeutics, leveraging its proprietary technology platforms to create advanced treatments that harness the power of the immune system. Cellerant aims to address significant unmet medical needs through its commitment to scientific excellence and patient-centric solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

17 Patents

#25 in Newark, CA

#4,521 in California

#18,913 in US

#35,974 in the World

Newark, CA (US)
Newark, CA, United States of America

Cellerant Therapeutics, Inc.

Forward Citations = 118

15 inventors:

goldMedal Holger Karsunky (10 out of 11 patents)

silverMedal Jagath Reddy Junutula (5 out of 38 patents)

bronzeMedal Ying-Ping Jiang (4 out of 9 patents)

4.  Vasu Jammalamadaka (3 out of 19 patents)

5.  Ping Jiang (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cellerant Therapeutics, Inc.. Retrieved from https://idiyas.com/company/cellerant-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…